CHINARES PHARMA's biopharmaceutical innovation drug "Puyouke" has been approved for new indications

AASTOCKS
2025.09.26 04:14

China Resources Pharmaceutical (03320.HK) announced that its subsidiary Tianjin Tasly Biological Pharmaceutical Co., Ltd. has received the "Drug Registration Certificate" issued by the National Medical Products Administration, approving the additional indication of the self-owned intellectual property biological innovative drug recombinant human urokinase (Pu You Ke) for thrombolytic treatment of acute ischemic stroke.

Pu You Ke is a Class 1 biological innovative drug approved during the "11th Five-Year Plan" period under the national "Major New Drug Creation" science and technology major project, with the indication for acute ST-segment elevation myocardial infarction. This acute ischemic stroke indication is the second indication approved for this drug in China

Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2026 Longbridge｜Disclaimer